Huons Global announced today (May 3rd, 2021) the appointment of Jay Jaemyung Choi, a global business & management expert, as the new CEO of the U.S. subsidiary, Huons USA.
Jay Choi was born in South Korea. After graduating from Sogang University's Department of Business Administration, he received his Master of Business Administration (MBA) from George Washington University. He served as the Head of the Treasury Department at SK's Hong Kong branch & Hong Kong joint venture and served as the CEO of a bio-venture ISTECH's U.S. subsidiary and Luminogene.
He later led overseas operations for Sigma Koki, a global manufacturer of photonics solutions, in Japan and Taiwan and then moved to OptoSigma Corporation, their U.S. subsidiary. He served as Chief Operationg Officer (COO).
Huons Global has significant plans to enter the U.S. local healthcare market with the appointment of its new head of Huons USA. CEO Jay Choi has plans to expand the Huons portfolio in the United States significantly, including but not limited to lidocaine injectables, PPE, LDS vaccine syringes, health functional foods, and medical devices, meeting the needs & trends of the local healthcare market.
Jay Choi, head of Huons USA, says, "I feel a great sense of responsibility and mission in leading the overseas subsidiary of a global healthcare company, Huons Group. I will do my best to produce exceptional results."
Huons USA is the U.S. corporation of Huons Group and was established in 2020. Huons Group is entering the United States market with biopharmaceuticals, medical devices, health functional foods, and other healthcare items.